Methods and compositions for treating sickle cell disease using a ferroportin inhibitor (VIT-2763)
Ferroportin inhibitor Compound 127 addresses the limitations of current SCD treatments by reducing hemolysis and iron overload, improving RBC parameters, and decreasing vascular occlusions, offering a safer and more effective therapeutic option for SCD.
Patent Information
- Application Number
- JP2022523485
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-05-25
- Filing Date
- 2020-10-22
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-10-22
AI Technical Summary
Current treatments for sickle cell disease (SCD) such as hydroxyurea, L-glutamine, crizanlizumab, and voxelotor have side effects and do not adequately address the underlying causes of symptoms like hemolysis, iron overload, and vascular occlusion, leading to chronic anemia and organ damage.
The use of a ferroportin inhibitor, Compound 127, which competes with hepcidin to inhibit ferroportin, reducing iron transport, thereby alleviating symptoms by decreasing hemolysis, iron overload, and vascular inflammation.
Compound 127 effectively reduces markers of hemolysis, iron levels, and vascular inflammation, improving RBC parameters, reducing organ iron accumulation, and decreasing the frequency and severity of vascular occlusions in SCD patients.
Smart Images

Figure 0007594004000021 
Figure 0007594004000022 
Figure 0007594004000023
Abstract
Description
[Background technology]
[0001] Sickle cell disease (SCD) is a genetic disorder of hemoglobin synthesis characterized by lifelong severe hemolytic anemia, recurrent pain crises, chronic organ damage, and significantly reduced life expectancy. SCD is caused by mutations in the hemoglobin (Hb) β gene, which result in amino acid substitutions in the β-globin protein, resulting in the sickle hemoglobin (HbS) allele βS. In a mouse model of SCD (Townes mice), the mouse Hb gene is deleted and replaced with the human sickle Hb gene. Mice homozygous for HbS express exclusively human sickle Hb and develop a pathology resembling human SCD, with rigid sickle red blood cells (sRBCs), hemolytic anemia, iron overload, enlarged splenic red pulp, inflammation, increased hemocyte adhesion to endothelial vasculature resulting in vaso-occlusion / vaso-obstruction (VO), and organ damage. Polymerization of deoxyHbS shortens the life span of sickle-shaped RBXC and promotes intravascular and extravascular hemolysis. Intravascular hemolysis releases cell-free Hb from RBCs. This cell-free Hb is then converted to ferrous iron (Fe 2+ ) to ferric iron (Fe 3+ )Hb (metHb), from which heme readily dissociates into the blood vessels, causing oxidative stress, inflammation, VO2, ischemia, and tissue damage (Umbreit J., Am. J. Hematol., 2007).
[0002] The traditional (approved) drugs to treat the associated SCD are hydroxyurea (Droxia, Hydrea, Cyclos), L-glutamine oral powder (Endari), crizanlizumab (Adakveo), and voxerotol (Oxbryta). [Prior art documents] [Patent documents]
[0003] [Patent Document 1] WO2017 / 068089A1 [Patent Document 2] WO2017068090A1 [Non-patent literature]
[0004] [Non-Patent Document 1] Umbreit J., Am. J. Hematol., 2007. Summary of the Invention [Problem to be solved by the invention]
[0005] Daily administration of hydroxyurea may reduce the frequency of pain crises and the need for blood transfusions and hospitalization, which may increase the risk of infection.
[0006] L-glutamine oral powder (Endari) helps reduce the frequency of pain attacks.
[0007] Crizanlizumab (Adakveo) is an intravenous drug that helps reduce the frequency of pain attacks. Side effects can include nausea, joint pain, back pain, and fever.
[0008] Voxelotor (Oxbryta) is an orally administered medication that corrects anemia in people with sickle cell disease. Side effects can include headache, nausea, diarrhea, fatigue, rash, and fever.
[0009] Additionally, patients with SCD are regularly given painkillers, which help relieve pain during sickle cell attacks but do not treat the cause of the pain.
[0010] An object of the present invention was to provide new and improved drugs or therapies for treating SCD. In particular, the new drug or SCD therapy should improve, alleviate, or alter one or more of the markers, symptoms, or events associated with SCD, toward normalized levels, as further defined herein. A further object of the present invention was to provide SCD drugs or therapies with an improved safety profile compared to conventional hydroxyurea therapy. A further object of the present invention was to provide SCD drugs or therapies with at least the same or even an improved safety profile compared to conventional voxerothol therapy. The present invention aims to provide improved SCD therapies, taking into account one or more aspects described in more detail herein below. [Means for solving the problem]
[0011] As used herein, a compound of the following formula (Compound 127): [ka] or a pharmaceutically acceptable salt thereof. Suitable salts include benzoate, HCl, citrate, fumarate, lactate, malate, maleate, methanesulfonate, phosphate, succinate, sulfate, tartrate, and toluenesulfonate. In various embodiments, the ratio of compound:salt is 1:1, 2:1, 1:2, or 1:3. As used herein, a salt of a compound refers to any ratio of compound:salt unless a specific ratio is indicated.
[0012] Compound 127 and methods for synthesizing compound 127 are described in WO2017 / 068089 and WO2017068090A1, which are incorporated herein by reference. Certain salts of compound 127, as well as various polymorphs of compound 127, are described in WO2018 / 192973, which is incorporated herein by reference. The potential use of certain salts disclosed therein in the treatment of sickle cell disease is mentioned in a list of various other indications. Example 13 describes single-dose intravenous and oral pharmacokinetic studies using the H2SO4 and HCl-mono salts of compound 127.
[0013] Vania Manolova: "First-in-class oral ferroportin inhibitor: mode of action and efficacy in a mouse model of beta-thalassemia intermedia"; EHA Abstract, 14.06.2019, discloses the use of compound 127 in the treatment of thalassemia intermedia, but does not mention any specific salt form of it. Furthermore, there is no mention therein of its potential effectiveness in the treatment of sickle cell disease.
[0014] JH Baek et al., "Ferroportin inhibition attenuates plasma iron, oxidant stress, and renal injury following red blood cell transfusion in guinea pigs"; TRANSFUSION, 00, 1-11, 2020, reported that intravenous administration of the small molecule ferroportin inhibitor VIT-2653 provided by Vifor (International) immediately after acute red blood cell transfusion in a guinea pig model resulted in attenuation of plasma iron, NTBI levels, oxidative stress, and cell damage.
[0015] The ferroportin-hepcidin axis regulates blood iron levels. Compound 127 competes with hepcidin for ferroportin binding and internalization. Compound 127 inhibits ferroportin, thereby inhibiting iron transport into the blood.
[0016] The terms "treat", "treatment" or "treating" in the context of the novel uses of the present invention include the amelioration of at least one symptom or pathological condition associated with SCD. The terms "treat", "treatment" or "treating" in the context of the present invention further include prophylaxis. Treatment with compound 127 according to the present invention in particular improves, alleviates or alters, for example towards normal levels, one or more of the following markers, symptoms or events:
[0017] Effect of treatment according to the present invention A particular aspect of the present invention relates to compound 127 as described anywhere herein for use in the treatment, prevention or amelioration of one or more of the markers, symptoms or events described above or below, or particularly those described in the Examples.
[0018] In some cases, treatment of a subject with SCD with Compound 127 reduces hemolysis (e.g., as assessed by a decrease in cell-free hemoglobin (Hb), a decrease in cell-free heme, a decrease in total bilirubin and indirect plasma bilirubin, or a decrease in serum LDH (lactate dehydrogenase)).
[0019] In some cases, treatment of a subject with SCD with Compound 127 improves one or more of total serum iron, serum ferritin, serum transferrin, and calculated TSAT (transferrin saturation).
[0020] In some cases, treatment of a subject with SCD with Compound 127 reduces reticulocytosis and improves reticulocyte count and / or % reticulocytes.
[0021] In some cases, treatment of a subject with SCD with Compound 127 reduces one or more of total Hb, RBC count, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (CHCM).
[0022] In some cases, treatment of a subject with SCD with Compound 127 improves one or more of RBC distribution width (RDW), platelet and reticulocyte counts.
[0023] In some cases, treatment of a subject with SCD with Compound 127 improves RBC microcytosis (RBC volume vs. Hb scattergram).
[0024] Optionally, treatment of a subject suffering from SCD with Compound 127 achieves a change in abnormal RBC (sickling) and / or improves RBC sickling (peripheral blood smear).
[0025] In some cases, treatment of a subject with SCD with Compound 127 reduces leukocytosis.
[0026] In some cases, treatment of a subject with SCD with Compound 127 reduces blood white blood cell counts (eg, reduces blood neutrophil counts and / or blood lymphocyte counts).
[0027] Optionally, treatment of a subject suffering from SCD with Compound 127 reduces extravascular and / or intravascular hemolysis.
[0028] In some cases, treatment of a subject with SCD with Compound 127 improves one or more markers of hemolysis, such as indirect / total bilirubin, circulating inflammatory markers measured by hsCRP (high sensitivity C-reactive protein), IL-1 and IL-6 (interleukins), TNF-α, sVCAM-1, endothelin-1, sP-selectin, sICAM-1, and xanthine oxidase.
[0029] In some cases, treatment of a subject with SCD with Compound 127 improves one or more of the following RBC indices: Hb concentration, RBC count, hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular Hb (MCH), mean corpuscular Hb concentration (MCHC), mean corpuscular Hb concentration (CHCM), RBC distribution width, platelet and reticulocyte count, % reticulocytes, % hypochromic, microcytic RBCs (RBC volume vs. Hb scatter plot), CHCM (mean corpuscular hemoglobin concentration), total serum iron, serum ferritin, serum transferrin, calculated TSAT, hepcidin, EPO (erythropoietin), NTBI (non-transferrin-bound iron), soluble transferrin receptor (sTFR), (sTFR-2), and LDH.
[0030] This means that the effectiveness of the compounds of the present invention in treating SCD can be assessed by measuring one or more of the parameters mentioned above and below, and compound 127 of the present invention is suitable for improving at least one of these parameters.
[0031] In the sense of the present invention, the term "ameliorate" or "improve" can include the modulation or change of the respective marker or symptom in the sense of a therapeutic effect.
[0032] More specifically, treating SCD according to the present invention may result in: A reduction in NTBI levels in at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or at least 100% of patients measured at any time within a period of up to 72 hours, up to 60 hours, up to 48 hours, up to 36 hours, up to 24 hours, or up to 12, 8, 6, 5, 4, 3, 2, 1, and 0.5 hours after administration, and compared to NTBI levels in the patient measured at any time within 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, or 48 hours, or up to <1 week, prior to initiation of a treatment of the invention.
[0033] A reduction in LPI levels in at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or at least 100% of patients measured at any time within a period of up to 72 hours, up to 60 hours, up to 48 hours, up to 36 hours, up to 24 hours, or up to 12, 8, 6, 5, 4, 3, 2, 1, and 0.5 hours after administration and compared to the total LPI levels in patients measured at any time within 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, or 48 hours, or up to <1 week, prior to initiation of a treatment of the invention.
[0034] An improvement in at least one of the parameters Hct, MCV, MCH, RDW, and reticulocyte count in a patient by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or at least 100% as measured at any time within a period of up to 1 week, up to 2 weeks, up to 3 weeks, up to 4 weeks, or up to 3 months after the first dose, and compared to the individual parameter in the subject measured at any time within 1 week, 2 weeks, 3 weeks, or 4 weeks prior to initiating a treatment of the present invention.
[0035] A reduction in serum ferritin levels in the patient of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or at least 100% as measured at any time within a period of up to 1 week, up to 2 weeks, up to 3 weeks, up to 4 weeks, or up to 3 months after the first administration, as compared to the serum ferritin level in the patient measured at any time within 1 week, 2 weeks, 3 weeks, or 4 weeks before initiating a treatment of the present invention.
[0036] In some cases, treatment of a subject with SCD with Compound 127 reduces or prevents further iron accumulation in the liver, kidneys and / or spleen.
[0037] Thus, in further embodiments, the new treatments may result in a reduction in liver, kidney, and / or spleen iron levels in SCD patients by at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or at least 100% as measured any time within a period of up to 1 week, up to 2 weeks, up to 3 weeks, up to 4 weeks, or up to 3 months after the first administration, as compared to the level of liver, kidney, and / or spleen iron levels in SCD patients measured any time within 1 week, 2 weeks, 3 weeks, or 4 weeks prior to initiation of a treatment of the invention.
[0038] In some cases, treatment with Compound 127 reduces renal iron overload.
[0039] In some cases, treatment of a subject with SCD with Compound 127 reduces the level of a marker of vascular inflammation, such as sVCAM-1.
[0040] In some cases, treatment of a subject suffering from SCD with Compound 127 reduces vascular inflammation.
[0041] In some cases, treatment of a subject with SCD with Compound 127 reduces adhesion of blood cells to inflamed veins or microvessels and improves blood flow in the microvessels.
[0042] In some cases, treatment of a subject with SCD with Compound 127 reduces adhesion of blood cells to microvessels, vascular occlusion (VO), and alleviates VO events.
[0043] In some cases, treatment of a subject with SCD with Compound 127 reduces the frequency of VOCs or painful VOC attacks and / or prevents the recurrence of painful VOCs, including ACS (acute chest syndrome).
[0044] In some cases, treatment of a subject suffering from SCD with Compound 127 reduces the frequency of VOCs or painful VOC attacks and / or prevents recurrent painful VOCs, including ACS, in the patient within 1 week, 2 weeks, 3 weeks, or 4 weeks, 2 months, 3 months, 4 months, 6 months, 8 months, 9 months, 12 months, or 24 months prior to initiation of a treatment of the invention; or achieves the SCD patient being free of VOCs or painful VOC attacks for at least 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 18 months, 24 months, or more following treatment.
[0045] In some cases, treatment of subjects with SCD with Compound 127 achieves a reduction in the mean number of pain (VOC) attacks over 48 weeks.
[0046] Optionally, treatment of subjects with SCD with Compound 127 achieves a reduction in the mean number of pain (VOC) attacks over 48 weeks in OH-urea naive patients.
[0047] A preferred embodiment relates to compound 127, as described anywhere herein, for use in the treatment, prevention or amelioration of vascular inflammation or VO and VO events.
[0048] In some cases, treatment of a subject suffering from SCD with Compound 127 reduces the need for RBC transfusions, particularly reducing the transfusion burden in the patient as compared to the transfusion burden in the patient within 1 week, 2 weeks, 3 weeks, or 4 weeks, 2 months, 3 months, 4 months, 6 months, 8 months, 9 months, 12 months, 24 months prior to initiating a treatment of the invention; or achieving red blood cell transfusion-free or red blood cell transfusion independence in the SCD patient for at least 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 18 months, 24 months or more following treatment.
[0049] In a further aspect, the novel treatment can result in an improvement in quality of life in an SCD patient compared to quality of life in an SCD patient determined within 1, 2, 3, or 4 weeks prior to initiation of a treatment of the invention. The improvement in quality of life is determined within 3, 6, 9, 12, 15, 18, 21, or 24 months after initiation of treatment. Quality of life can be determined by assessing changes in patient-reported outcomes (PROs) using the Adult Sickle Cell Disease Quality of Life Measurement System (ASCQ-ME).
[0050] Measurement of the above-defined parameters can be carried out using conventional methods in the art, in particular by the methods described in unpublished PCT application PCT / EP2020 / 070391, the content of each of which is incorporated herein by reference.
[0051] Patient population treated Essentially, the subjects to be treated in the new uses according to the invention can be any mammal, such as rodents and primates, and in a preferred embodiment, the new medical uses relate to the treatment of humans. A subject suffering from SCD and to be treated with the new methods according to the invention is also referred to as a "patient."
[0052] The subjects to be treated can be of any age. Preferred embodiments of the present invention relate to the treatment of children and adolescents. Accordingly, in preferred embodiments of the present invention, the subjects treated with the new methods described herein are ≦18 years of age. More specifically, the subjects to be treated with the new methods described herein are ≦16 years of age, ≦15 years of age, ≦14 years of age, ≦13 years of age, ≦12 years of age, ≦11 years of age, ≦10 years of age, ≦9 years of age, ≦8 years of age, ≦7 years of age, ≦6 years of age, or ≦5 years of age. In further embodiments of the present invention, the subjects to be treated with the new methods described herein are 1-3 years of age, 3-5 years of age, 5-7 years of age, 7-9 years of age, 9-11 years of age, 11-13 years of age, 13-15 years of age, 15-20 years of age, 20-25 years of age, 25-30 years of age, or >30 years of age. Preferably, the pediatric patients to be treated are ≦16 years of age or ≦12 years of age. When treating children, the subjects treated with the new methods described herein are preferably ≥ 2 years old, preferably ≥ 2 years old and ≤ 16 years old or ≤ 12 years old.
[0053] In further embodiments of adult and adolescent treatment, the patient is ≥12 years of age or ≥16 years of age.
[0054] When treating adults, subjects treated with the new methods described herein are between 18 and 50 years of age, preferably between 18 and 25 years of age, 20 and 25 years of age, 25 and 30 years of age, 30 and 35 years of age, 35 and 40 years of age, 40 and 45 years of age, or 45 and 50 years of age. It is also possible to treat elderly subjects, such as those between 50 and 55 years of age, 55 and 60 years of age, or older than 60 years of age. When treating elderly subjects, subjects treated with the new methods described herein are between 60 and 80 years of age, such as those between 60 and 65 years of age, 65 and 70 years of age, 70 and 75 years of age, 75 and 80 years of age, or older than 80 years of age.
[0055] The treatment of children and adolescents is particularly preferred, as treatment with the compounds of the present invention provides significant benefits. The compounds can be administered orally, which is advantageous over parenteral administration. Furthermore, the orally bioavailable compounds of the present invention are known to have reasonable bioavailability and half-life in the body, resulting in relatively rapid elimination. This results in fewer side effects and faster drug reversibility, which is particularly important in the treatment of children.
[0056] Compound 127 can be used to treat patients with various forms of SCD, including HbSS, HbSC, HbSβ0 thalassemia, HbSβ+ thalassemia, HbSD, HbSE, and HbSO. In particular, compound 127 can be used to treat patients suffering from HbSS or HbSβ0 thalassemia.
[0057] Compound 127 can be used, inter alia, to treat patients suffering from SCD, as defined anywhere herein, that is not adequately controlled by monotherapy with, for example, hydroxyurea.
[0058] Compound 127 can be used to treat patients with SCD as described herein who have one or more VOCs per year.
[0059] Compound 127 can be used to treat patients with SCD as described herein who have more than one and less than six VOCs per year.
[0060] Compound 127 can be used to treat patients suffering from SCD as described herein who have absolute and % reticulocyte counts >1.5 x the upper limit of normal (ULN).
[0061] Compound 127 can be used to treat patients with a history of partial or total splenectomy, patients with a history or clinically significant findings of cardiac or pulmonary disorders, and / or patients who have received, frequently or regularly receive red blood cell (RBC) transfusion therapy (including chronic, prophylactic or preventive transfusions to treat SCD).
[0062] Dosage form The compounds according to the invention are preferably provided in medicaments or pharmaceutical compositions in oral administration forms including, for example, pills, tablets, e.g. enteric coated tablets, film tablets and layered tablets, sustained release formulations for oral administration, depot formulations, dragees, granules, emulsions, powders, microcapsules, microformulations, nanoformulations, liposomal formulations, capsules, e.g. enteric coated capsules, powders, microcrystalline formulations, dusting powders, drops, ampoules, solutions and suspensions.
[0063] In a preferred embodiment of the invention, the compounds according to the invention are administered in the form of tablets or capsules as defined above. More preferred are capsules filled with the drug compound 127. These can be present, for example, in an acid-resistant form or with a pH-dependent coating.
[0064] The drug compound may be filled into the capsules as the pure drug substance or in the form of a pharmaceutical composition containing additional pharmaceutically acceptable adjuvants, auxiliary agents, solvents, additives and the like.
[0065] In general, dosage forms containing the compounds of the present invention may also contain additional pharmaceutically acceptable adjuvants, adjuvants, fillers, solvents, additives, and the like.
[0066] The pharmaceutical composition may, for example, comprise up to 99% by weight, or up to 90% by weight, or up to 80% by weight, or up to 70% by weight of a drug compound of the invention, the remainder being formed by pharmacologically acceptable carriers and / or adjuvants and / or solvents and / or optionally further pharmaceutically active compounds, respectively.
[0067] Pharmaceutically acceptable carriers, adjuvants, or solvents are common pharmaceutical carriers, adjuvants, or solvents, including various organic or inorganic carriers and / or adjuvants commonly used for pharmaceutical purposes, particularly for solid pharmaceutical formulations. Examples include excipients (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate); binders (e.g., cellulose, methylcellulose, hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, starch); disintegrants (e.g., starch, hydrolyzed starch, carboxymethylcellulose, calcium salt of carboxymethylcellulose, hydroxypropyl starch, sodium starch glycolate, sodium bicarbonate, calcium phosphate, calcium citrate); lubricants (e.g., magnesium stearate, talc, calcium carbonate, calcium carbonate); cellulose, sodium lauryl sulfate); flavoring agents (e.g., citric acid, menthol, glycine, orange powder); preservatives (e.g., sodium benzoate, sodium bisulfite, parabens (e.g., methylparaben, ethylparaben, propylparaben, butylparaben)); stabilizers (e.g., citric acid, sodium citrate, acetic acid, and the titriplex series of polycarboxylic acids, such as diethylenetriaminepentaacetic acid (DTPA)); suspending agents (e.g., methylcellulose, polyvinylpyrrolidone, aluminum stearate); dispersing agents; diluents (e.g., water, organic solvents); waxes, fats, and oils (e.g., beeswax, cocoa butter); polyethylene glycol; white petrolatum, etc.
[0068] Liquid pharmaceutical formulations, such as solutions, suspensions, and gels, typically contain a liquid carrier such as water and / or a pharmaceutically acceptable organic solvent. Furthermore, such liquid formulations may contain, for example, pH adjusters, emulsifiers or dispersants, buffers, preservatives, wetting agents, gelatinizing agents (e.g., methylcellulose), dyes, and / or flavoring agents, as defined above. The composition may be isotonic, i.e., have the same osmotic pressure as blood. The isotonicity of the composition can be adjusted by using sodium chloride and other pharmaceutically acceptable agents, such as dextrose, maltose, boric acid, sodium tartrate, propylene glycol, and other inorganic or organic soluble substances. The viscosity of the liquid composition can be adjusted by using a pharmaceutically acceptable thickener, such as methylcellulose. Other suitable thickeners include, for example, xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, and carbomer. The preferred concentration of the thickener depends on the drug selected.
[0069] Pharmaceutically acceptable preservatives can be used to extend the shelf life of the liquid compositions, for example, benzyl alcohol may be suitable, although several preservatives can also be used, including parabens, thimerosal, chlorobutanol, and benzalkonium chloride.
[0070] Thus, a further aspect of the present invention relates to compounds according to the present invention, including pharmaceutically acceptable salts, solvates, hydrates and polymorphs thereof, and to medicaments, compositions and combined preparations comprising same in oral dosage form for use in the treatment of SCD as defined herein.
[0071] Administration The compounds according to the invention for use according to the invention may be administered by one of the following administration routes.
[0072] In one embodiment, the compounds according to the present invention can be administered to a patient in need of treatment at a dose of 0.001 to 500 mg, for example, 1 to 4 times daily, preferably 1 or 2 times daily, although the dose can be increased or decreased depending on the age, weight, symptoms of the patient, severity of the disease, or type of administration. In a further embodiment of the invention, the compounds of the invention may be administered at 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 125 mg, 130 mg, 145 mg, 150 mg, 165 mg, 175 mg, 180 mg, 195 mg, 200 mg, 250 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 305 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg.
[0073] The dosage is preferably 0.5 to 500 mg, more preferably 1 to 300 mg or 3 to 300 mg, and even more preferably 1 to 250 mg or 5 to 250 mg.
[0074] Most preferred are doses of 5 mg, 15 mg, 30 mg, 60 mg, 120 mg, or 240 mg. Particularly preferred are doses of 30 mg, 60 mg, 90 mg, 120 mg, or 240 mg, and even more particularly preferred are doses of 30 mg, 60 mg, 90 mg, or 120 mg. Most preferred are doses of 30 mg, 60 mg, and 120 mg.
[0075] The dosages defined above can be administered in a single daily dose as a total daily dose or divided into subdoses for administration two or more times daily.
[0076] In further preferred embodiments, a daily dose of 30 mg, 60 mg, 90 mg, or 120 mg is preferably administered as a single dose once daily. In further preferred embodiments, a daily dose of 60 mg or 120 mg is administered twice daily, as two 30 mg or two 60 mg doses, respectively. A daily dose of 90 mg can also be administered as a 30 mg dose three times daily.
[0077] In further embodiments, doses of 0.001 to 60 mg / kg, 0.01 to 60 mg / kg, 0.1 to 60 mg / kg, or 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, and 60 mg / kg can be administered. A dose of 120 mg or up to 240 mg can be administered to patients weighing 50 kg or more, and 60 mg can be administered to patients weighing 50 kg or more, once or twice daily, respectively. It is preferred to administer 60 mg to patients weighing 50 kg or more, and 30 mg to patients weighing 50 kg or less, once or twice daily in each case. Furthermore, it is preferred to administer the doses of 30 mg and 60 mg defined above to patients weighing 50 kg or more but not exceeding 100 kg.
[0078] Generally, weight-adjusted dosing is possible and in further embodiments preferred.
[0079] It is also preferred to administer the compounds of the invention in an age-appropriate formulation, particularly pediatric dosage forms for patients aged 2 years and older, which require specific dosage forms, examples of which include syrups, solutions, drops, or formulations for dissolution in a liquid drink.
[0080] In a further embodiment, one of the doses defined above can be selected as an initial dose, followed by one or more administrations of the same or modified doses as defined above, repeated at intervals of 1 to 7 days, 1 to 5 days, preferably 1 to 3 days, or every two days.
[0081] The initial dose and subsequent doses can be selected from among the doses defined above and adjusted / varied according to the patient's needs within the ranges provided.
[0082] In particular, the subsequent doses can be appropriately selected according to the individual patient, the course of the disease, and the therapeutic effect, and can be administered once, twice, three times, four times, five times, six times, seven times, or more times.
[0083] An initial dose may be equal to or different from one or more subsequent doses, and further, the subsequent doses may be equal or different.
[0084] The interval between repeat administrations can be the same length or can vary depending on the individual patient, the course of the disease and the treatment response.
[0085] Preferably, the subsequent doses decrease with increasing frequency of subsequent administrations.
[0086] Preferably, a dose of 3 mg to 300 mg, more preferably 5 mg to 250 mg, and most preferably 5 mg, 15 mg, 30 mg, 60 mg, 90 mg, 120 mg, or 240 mg is administered once daily for a treatment period of at least 3 days, at least 5 days, at least 7 days, and up to 4 weeks. In a further preferred embodiment, a dose of 30 mg, 60 mg, or 120 mg is administered once daily. In a further preferred embodiment, administration of a total daily dose of 30 mg, 60 mg, or 120 mg is achieved by administering doses of 15 mg, 30 mg, or 60 mg twice daily, respectively.
[0087] In a further embodiment, administration of a total daily dose of 240 mg is achieved by administering 120 mg doses twice daily.
[0088] In a further embodiment, the dosage is varied by administering an initial dose selected from the doses defined above for one, two, three, four, or more weeks, followed by an increased dose selected from the doses defined above for another one, two, three, four, or more weeks. Depending on the treatment outcome, it is also possible to start with a higher initial dose for the period defined above, and then reduce the dose during subsequent treatment intervals. Preferably, an initial daily dose of 30 mg or 60 mg is administered for four weeks, followed by the same dose for another four weeks, or by an increased dose for another four weeks. Such a dosing regimen may include administering 30 mg daily for four weeks, followed by 60 mg daily for another four weeks.
[0089] In particular, doses up to a total daily dose of 240 mg have been shown to be safe and well tolerated. The preferred administration method has also demonstrated rapid oral absorption, with detectable levels occurring as early as 15-30 minutes after administration. Absorption levels remain stable even with repeated administration, with no critical accumulation observed.
[0090] This preferred method of administration has also been shown to effectively reduce mean serum iron levels and calculated mean transferrin saturation, indicating its effectiveness in treating SCD.
[0091] Combination therapy A further object of the present invention relates to a medicament or combination preparation comprising a compound of the present invention and at least one additional pharmaceutically active compound ("combination therapy compound"), preferably the additional active compound being useful for the treatment of SCD. The combination therapy compound can be selected from active compounds used in the prevention and treatment of iron overload and related conditions, including iron chelating compounds, or compounds for the prevention and treatment of any of the conditions, disorders, or diseases associated with or caused by iron overload. Suitable combination therapy compounds can be selected from pharmaceutically active compounds for the prevention and treatment of SCD, thalassemia, hemochromatosis, neurodegenerative diseases (e.g., Alzheimer's disease or Parkinson's disease), and related conditions. Preferably, the at least one additional pharmaceutically active combination therapy compound is selected from agents for treating SCD, such as hydroxyurea, voxerotol, ADAKVEO® (crizanlizumab), L-glutamine oral powder (Endari), fetal hemoglobin (HbF) inducers, inhibitors of PDE9 (e.g., IMR-687), and / or pain relievers. The most preferred combination therapy compounds from this class of drugs for treating SCD are fetal hemoglobin (HbF) inducers.
[0092] The at least one additional pharmaceutically active combination therapy compound may further be selected from agents that reduce iron overload (e.g., Tmprss6-ASO) and iron chelators, particularly curcumin, SSP-004184, deferithrine, deferasirox, deferoxamine, and deferiprone, and JAK2 inhibitors. The most preferred combination therapy compound from the group of iron chelators is deferasirox.
[0093] Further preferred combination therapy compounds can be selected from drugs for treating β-thalassemia, such as luspatercept, Lentiglobin BB305 (a gene therapy synthetic human hepcidin (LJPC-401), hepcidin peptidomimetic PTG-300 and Tmprss6 (IONIS-TMPRSS6-L RX) targeted antisense oligonucleotide developed by the company Bluebird Bio).
[0094] In a further aspect, the present invention relates to a novel use and medical treatment as defined herein, wherein a compound as defined herein is administered to a patient in need of treatment in combination therapy with one or more of the combination therapy compounds as defined above, in a fixed dose or free dose combination for sequential use. Such combination therapy comprises the simultaneous administration of a compound as defined herein with at least one additional pharmaceutically active compound (drug / combination therapy compound).
[0095] Combination therapy in fixed dose combination therapy involves the simultaneous administration of a compound as defined herein and at least one additional pharmaceutically active compound in a fixed dose formulation.
[0096] Combination therapy in free dose combination therapy includes the simultaneous administration of a compound as defined herein and at least one additional pharmaceutically active compound in free doses of the individual compounds, either by simultaneous administration of the individual compounds or by sequential use of the individual compounds spread over a period of time.
[0097] In a particularly preferred embodiment, the combination therapy comprises simultaneous oral administration of Compound No. 127 and a combination therapy compound from the group of SCD medications, preferably hydroxyurea and / or pain relievers.
[0098] A further aspect of the present invention relates to a combination therapy as described herein, wherein the pharmaceutical compound is one selected from those described in WO2020 / 123850A1, particularly one of the specific exemplary compounds thereof described below.
[0099] A further aspect relates to the provision of novel combination therapies for treating SCD by administering compound 127 described herein in combination with voxerotol, ADAKVEO® (crizanlizumab), L-glutamine oral powder (Endari), fetal hemoglobin (HbF) inducers, inhibitors of PDE9 (such as IMR-687), and / or pain relief medications. The most preferred combination therapy compounds from this group of agents for treating SCD in combination with compound 127 are fetal hemoglobin (HbF) inducers.
[0100] Further useful compounds Other useful compounds for treating SCD are described in WO2017 / 068089, WO2017068090A1, and WO2018 / 192973. Accordingly, in some embodiments, a patient is treated by administering a compound of formula (I): [ka] During the ceremony, X 1 is N or O; and X 2 is N, S or O; However, X 1 and X 2 are different; R 1 teeth, -hydrogen and -Optionally substituted alkyl selected from the group consisting of: n is an integer from 1 to 3; A 1 and A 2 are independently selected from the group of alkanediyls; R 2 teeth, hydrogen, or -Optionally substituted alkyl and; or A 1 and R 2together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered ring; R 3 represents one, two or three optional substituents, each of which is independently halogen, Cyano, optionally substituted alkyl, optionally substituted alkoxy, and carboxyl group may be selected from the group consisting of: R 4 teeth, hydrogen, halogen, C1-C3-alkyl, and Halogen-substituted alkyl is selected from the group consisting of:
[0101] In some embodiments, n=1; R 2 = hydrogen; R 3 = hydrogen; R 4 = hydrogen; A 1 = methylene or ethane-1,2-diyl; A 2 = methylene, ethane-1,2-diyl or propane-1,3-diyl; or A 1 and R 2 together with the nitrogen atom to which they are attached form an optionally substituted four-membered ring, forming a compound according to formula (II) or formula (III): [ka] Form TIFF0007594004000004.tif34143, Here, in formulas (II) and (III), m is an integer of 1, 2, or 3; X 1 , X 2 , and R 1has the defined meaning for compounds according to formula (I).
[0102] In some embodiments, the patient is treated with a compound selected from the group consisting of: and pharmaceutically acceptable salts thereof:
[0103] [Table 1]
[0104] In a further preferred embodiment, the present invention relates to new uses and methods of treatment as defined herein, wherein the compound of formula (I), (II) or (III) is selected from the group consisting of:
[0105] [Table 2]
[0106] In a further preferred embodiment, the present invention relates to new uses and methods of treatment as defined herein, wherein the compound of formula (I), (II) or (III) is selected from the group consisting of:
[0107] [Table 3]
[0108] In some embodiments, the method comprises administering a compound selected from the following: and pharmaceutically acceptable salts thereof: [ka]
[0109] In Formulas I, II and III, the substituents are defined as follows: Optionally substituted alkyl preferably comprises straight-chain or branched alkyl, preferably containing 1 to 8, more preferably 1 to 6, particularly preferably 1 to 4, even more preferably 1, 2 or 3 carbon atoms, also designated as C1-C4-alkyl or C1-C3-alkyl.
[0110] Optionally substituted alkyl further includes cycloalkyl, preferably containing from 3 to 8, more preferably 5 or 6 carbon atoms.
[0111] Examples of alkyl residues containing 1 to 8 carbon atoms include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, i-pentyl, sec-pentyl, t-pentyl, 2-methylbutyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1-ethyl-1-methylpropyl, n-heptyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 1-ethylpentyl, 2-methylpentyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 1-ethylpentyl, 2-methylpentyl, 3-ethylbutyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1-ethyl-1-methylpropyl, n-heptyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 1-ethylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylhexyl, 5-methylhexyl, 2-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 5-methylhexyl, 2-methylpent ... Examples of alkyl groups include butyl, 2-ethylpentyl, 3-ethylpentyl, 4-ethylpentyl, 1,1-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 4,4-dimethylpentyl, 1-propylbutyl, n-octyl, 1-methylheptyl, 2-methylheptyl, 3-methylheptyl, 4-methylheptyl, 5-methylheptyl, 6-methylheptyl, 1-ethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 5-ethylhexyl, 1,1-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 5,5-dimethylhexyl, 1-propylpentyl, and 2-propylpentyl groups. Those containing 1 to 4 carbon atoms (C1-C4-alkyl), such as, in particular, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and t-butyl, are preferred. C1-C3 alkyl, in particular methyl, ethyl, propyl and i-propyl, are more preferred. C1 and C2 alkyl, such as methyl and ethyl, are most preferred.
[0112] Cycloalkyl residues containing 3 to 8 carbon atoms preferably include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. Cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl groups are preferred. Cyclopropyl is particularly preferred.
[0113] Substituents for optionally substituted alkyl as defined above preferably include, for example, halogen as defined below, such as preferably F, cycloalkyl as defined above, such as preferably cyclopropyl, optionally substituted heteroaryl as defined below, such as preferably a benzimidazolyl group, optionally substituted amino as defined below, such as preferably an amino group or a benzyloxycarbonylamino group, carboxyl groups, aminocarbonyl groups as defined below, and alkylene groups, such as in particular methylene-substituted ethyl groups (CH3-(C=CH2)- or [ka] , in the formula, * indicates the point of attachment.)
[0114] Halogen includes fluorine, chlorine, bromine and iodine, preferably fluorine or chlorine, with fluorine being most preferred.
[0115] Examples of linear or branched alkyl residues containing 1 to 8 carbon atoms substituted by halogen include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, tribromomethyl, 1-fluoroethyl, 1-chloroethyl, 1-bromoethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, difluoroethyl (e.g., 1,2-difluoroethyl), 1,2-dichloroethyl, ... Ethyl group, 1,2-dibromoethyl group, 2,2-difluoroethyl group, 2,2-dichloroethyl group, 2,2-dibromoethyl group, 2,2,2-trifluoroethyl group, heptafluoroethyl group, 1-fluoropropyl group, 1-chloropropyl group, 1-bromopropyl group, 2-fluoropropyl group, 2-chloropropyl group, 2-bromopropyl group, 3-fluoropropyl group, 3-chloropropyl group, 3-bromopropyl group, 1,2-difluoropropyl group, 1,2-dichloropropyl group, 1,2-dibromo Propyl group, 2,3-difluoropropyl group, 2,3-dichloropropyl group, 2,3-dibromopropyl group, 3,3,3-trifluoropropyl group, 2,2,3,3,3-pentafluoropropyl group, 2-fluorobutyl group, 2-chlorobutyl group, 2-bromobutyl group, 4-fluorobutyl group, 4-chlorobutyl group, 4-bromobutyl group, 4,4,4-trifluorobutyl group, 2,2,3,3,4,4,4-heptafluorobutyl group, perfluorobutyl group, 2-fluoropentyl group, 2-chloropentyl group Examples of such groups include fluoroalkyl, 2-bromopentyl, 5-fluoropentyl, 5-chloropentyl, 5-bromopentyl, perfluoropentyl, 2-fluorohexyl, 2-chlorohexyl, 2-bromohexyl, 6-fluorohexyl, 6-chlorohexyl, 6-bromohexyl, perfluorohexyl, 2-fluoroheptyl, 2-chloroheptyl, 2-bromoheptyl, 7-fluoroheptyl, 7-chloroheptyl, 7-bromoheptyl, and perfluoroheptyl groups. Particularly mentioned are fluoroalkyl, difluoroalkyl, and trifluoroalkyl, with trifluoromethyl and mono- and di-fluoroethyl being preferred. Trifluoromethyl is particularly preferred.
[0116] Examples of cycloalkyl-substituted alkyl groups include the above alkyl residues containing 1 to 3, preferably 1, cycloalkyl, such as cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethylcyclohexylmethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl2-cyclohexylethyl, 2- or 3-cyclopropylpropyl, 2- or 3-cyclobutylpropyl, 2- or 3-cyclopentylpropyl, 2- or 3-cyclohexylpropyl, etc. Preferred is cyclopropylmethyl.
[0117] Examples of heteroaryl-substituted alkyl groups include the above alkyl residues containing 1 to 3, preferably 1, (optionally substituted) heteroaryl groups, such as pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, imidazolyl, benzimidazolyl, thiophenyl or oxazolyl groups, such as pyridin-2-yl-methyl, pyridin-3-yl-methyl, pyridin-4-yl-methyl, 2-pyridin-2-yl-ethyl, 2-pyridin-1-yl-ethyl ... pyridazin-3-yl-ethyl, pyridazin-3-yl-methyl, pyrimidin-2-yl-methyl, pyrimidin-4-yl-methyl, pyrazin-2-yl-methyl, pyrazol-3-yl-methyl, pyrazol-4-yl-methyl, pyrazol-5-yl-methyl, imidazol-2-yl-methyl, imidazol-5-yl-methyl, benzimidazol-2-yl-methyl, thiophen-2-yl-methyl, thiophen-3-yl-methyl, 1,3-oxazol-2-yl-methyl.
[0118] Preferred are alkyl groups substituted with benzimidazolyl groups, such as benzimidazol-2-yl-methyl and benzimidazol-2-yl-ethyl.
[0119] Examples of amino-substituted alkyl residues include the above alkyl residues containing one to three, preferably one, (optionally substituted) amino groups as defined below, for example aminoalkyl (NH-alkyl) or mono- or dialkylamino-alkyl, such as aminomethyl, 2-aminoethyl, 2- or 3-aminopropyl, methylaminomethyl, methylaminoethyl, methylaminopropyl, 2-ethylaminomethyl, 3-ethylaminomethyl, 2-ethylaminoethyl, 3-ethylaminoethyl, etc. (3-aminopropyl is preferred), or alkyl groups optionally substituted with optionally substituted alkyloxycarbonylamino groups, such as groups according to the formula [ka] In the formula, R defines a phenyl group, forming a benzyloxycarbonylaminopropyl group.
[0120] The optionally substituted amino preferably includes amino (-NH2), optionally substituted mono- or dialkylamino (alkyl-NH-, (alkyl)2N-), and for "alkyl", the definition of optionally substituted alkyl can be referred to above. Preferred are mono- or dimethylamino, mono- or diethylamino, and monopropylamino. Most preferred are amino group (-NH2) and monopropylamino.
[0121] Furthermore, a carboxyl group refers to the group [-(C=O)-OH], and an aminocarbonyl group refers to the group [NH2-(C=O)-].
[0122] The optionally substituted alkoxy includes an optionally substituted alkyl-O- group, and reference can be made to the definition of the alkyl group above. Preferred alkoxy groups are straight-chain or branched alkoxy groups containing up to 6 carbon atoms, such as methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, sec-butyloxy, t-butyloxy, n-pentyloxy, i-pentyloxy, sec-pentyloxy, t-pentyloxy, 2-methylbutoxy, n-hexyloxy, i-hexyloxy, t-hexyloxy, sec-hexyloxy, 2-methylpentyloxy, 3-methylpentyloxy, 1-ethylbutyloxy, 2-ethylbutyloxy, 1,1-dimethylbutyloxy, 2,2-dimethylbutyloxy, 3,3-dimethylbutyloxy, 1-ethyl-1-methylpropyloxy, and cycloalkyloxy groups, such as cyclopentyloxy or cyclohexyloxy. Methoxy, ethoxy, n-propyloxy and i-propyloxy groups are preferred, methoxy and ethoxy groups are more preferred, and methoxy is particularly preferred.
[0123] The optionally substituted alkanediyl is preferably a divalent straight-chain or branched alkanediyl group having 1 to 6, preferably 1 to 4, more preferably 1, 2 or 3 carbon atoms, which may have 1 to 3, preferably 1 or 2, substituents selected from the group consisting of halogen, hydroxyl (—OH), oxo group ((═O; forming a carbonyl or acyl group [—(C═O)—]), and an alkyl group as defined above, for example, preferably methyl. Preferred examples include methylene, ethane-1,2-diyl, ethane-1,1-diyl, propane-1,3-diyl, propane-1,1-diyl, and the like. Examples of the alkoxy group include pentane-1,5-diyl, propane-1,2-diyl, propane-2,2-diyl, butane-1,4-diyl, butane-1,2-diyl, butane-1,3-diyl, butane-2,3-diyl, butane-1,1-diyl, butane-2,2-diyl, butane-3,3-diyl, and pentane-1,5-diyl. Particularly preferred are methylene, ethane-1,2-diyl, ethane-1,1-diyl, propane-1,3-diyl, propane-2,2-diyl, and butane-2,2-diyl. Most preferred are methylene, ethane-1,2-diyl, and propane-1,3-diyl.
[0124] Preferred substituted alkanediyl groups are hydroxy-substituted alkanediyl, such as hydroxy-substituted ethanediyl, oxo-substituted alkanediyl, such as oxo-substituted methylene or ethanediyl groups, forming carbonyl or acyl (acetyl) groups, halogen-substituted alkanediyl groups.
[0125] Optionally, A has the meaning of a linear or branched alkanediyl group as defined above. 1 and R having the meaning of an optionally substituted alkyl group as defined above. 2 together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered ring, which may be substituted with 1 to 3 substituents as defined above. 1 and R 2 can together form a group according to one of the following formulae: [ka] In this case, a (substituted or unsubstituted) four-membered ring formation is preferred, such as, in particular, the following groups: [ka] In this case, the left-hand binding site is at position X in formula (I). 1 and X 2 The point of attachment to the 5-membered heterocyclic ring between the two groups indicates the point of attachment to the group A2, which has the meaning of an alkanediyl group as defined herein.
[0126] In formula (I) as defined herein, n has the meaning of an integer from 1 to 3, for example 1, 2 or 3, and thus represents a methylene group, an ethane-1,2-diyl group or a propane-1,3-diyl group. More preferably, n is 1 or 2, and even more preferably, n is 1, representing a methylene group.
[0127] In some embodiments, A) X 1 is N or O; X 2 is N, S or O; However, X 1 and X 2 are different; Thus, a five-membered heterocycle according to the formula: [ka] Forming During the ceremony, * indicates the point of attachment to the aminocarbonyl group, ** is A 1 The point of attachment to the group is indicated.
[0128] B) n is an integer of 1, 2 or 3; preferably, n is 1 or 2, and more preferably, n is 1.
[0129] C) R1 teeth, -hydrogen and - optionally substituted alkyl (as defined above) selected from the group consisting of: Preferably, R 1 is hydrogen or methyl, more preferably R 1 is hydrogen.
[0130] D) R 2 teeth, hydrogen, and - optionally substituted alkyl (as defined above) selected from the group consisting of: Preferably, R 2 is hydrogen or C1-C4-alkyl, more preferably R 2 is hydrogen or methyl, and even more preferably, R 2 is hydrogen.
[0131] E) R 3 represents one, two or three optional substituents, which are independently halogen (as defined above), -Cyano, optionally substituted alkyl (as defined above); optionally substituted alkoxy (as defined above), and - carboxyl group (defined above) may be selected from the group consisting of: Preferably, R 3 represents one or two optional substituents, which are independently -halogen, -Cyano, alkyl (as defined above) optionally substituted with 1, 2 or 3 halogen atoms (as defined above); optionally substituted alkoxy (as defined above), and Carboxyl group (defined above) may be selected from the group consisting of: More preferably, R 3represents one or two optional substituents, which are independently -F and Cl, -Cyano, -trifluoromethyl, -methoxy, and -Carboxyl group may be selected from the group consisting of: Even more preferably, R 3 is hydrogen and represents the unsubstituted terminal benzimidazolyl ring in formula (I).
[0132] F) R 4 teeth, -hydrogen, halogen (as defined above), -C1-C3-alkyl, and -halogen-substituted alkyl (as defined above) selected from the group consisting of: Preferably, R 4 teeth, -hydrogen, -Cl, -methyl, ethyl, iso-propyl, and -trifluoromethyl selected from the group consisting of: More preferably, R 4 teeth, -hydrogen, -Cl, -methyl, and -trifluoromethyl selected from the group consisting of: More preferably, R 4 teeth, -hydrogen, -Cl, and -methyl selected from the group consisting of: Even more preferably, R 4 is hydrogen.
[0133] G) A 1 is an alkanediyl, Preferably, A 1is methylene or ethane-1,2-diyl, more preferably A 1 is ethane-1,2-diyl.
[0134] H) A 2 is an alkanediyl, Preferably, A 2 is methylene, ethane-1,2-diyl or propane-1,3-diyl, More preferably, A 2 is methylene or ethane-1,2-diyl, and even more preferably, A 2 is ethane-1,2-diyl.
[0135] I) or A 1 and R 2 together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered ring as defined above; In that case, A 1 and R 2 together with the nitrogen atom to which they are attached preferably form an optionally substituted four-membered ring as defined above, In that case, A 1 and R 2 together with the nitrogen atom to which they are attached, more preferably form an unsubstituted four-membered ring (azetidinyl ring).
[0136] Here, the substituents of the compounds of formula (I) below can in particular have the following meanings: n has any of the meanings according to B) above, and the remaining substituents can have any of the meanings defined in A) and C) to I).
[0137] R 1 has any of the meanings according to C) above, and the remaining substituents can have any of the meanings defined in A) and B) and D) to I).
[0138] R 2has any of the meanings according to D) above, and the remaining substituents can have any of the meanings defined in A) to C) and E) to H) or I).
[0139] R 3 has any of the meanings according to E) above, and the remaining substituents can have any of the meanings defined in A) to D) and F) to I).
[0140] R 4 has any of the meanings given in F) above, and the remaining substituents can have any of the meanings defined in A) to E) and G) to I).
[0141] A 1 has any of the meanings according to G) above, and the remaining substituents can have any of the meanings defined under A) to F) and H) or I).
[0142] A 2 has any of the meanings given in H) above, and the remaining substituents can have any of the meanings defined in A) to G) and I).
[0143] R 2 and A 1 has any of the meanings defined in I), and the remaining substituents can have any of the meanings defined in A) to C), E), F) and H).
[0144] In some cases, X 1 is N or O; X 2 is N, S or O; provided that X 1 and X 2 are different;R 1 is hydrogen; n is 1, 2 or 3; A 1 is methylene or ethane-1,2-diyl; A 2 is methylene, ethane-1,2-diyl or propane-1,3-diyl; R 2 is hydrogen or C1-C4-alkyl; or A 1 and R2 together with the nitrogen atom to which they are attached form an optionally substituted four-membered ring; R 3 represents one or two optional substituents, which are -halogen, -Cyano, alkyl optionally substituted by 1, 2 or 3 halogen atoms, optionally substituted alkoxy, and -Carboxyl group may be selected from the group consisting of: R 4 teeth, -hydrogen, -Cl, -methyl, ethyl, iso-propyl, and -trifluoromethyl or a salt thereof.
[0145] Optionally, the salt is selected from salts of the compound of formula (I) with an acid selected from the group consisting of benzoic acid, citric acid, fumaric acid, hydrochloric acid, lactic acid, malic acid, maleic acid, methanesulfonic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid and toluenesulfonic acid, characterized in that the ratio of compound (I):acid is 1-2:1-3.
[0146] In some cases of compounds of general formula I, X 1 is N or O; X 2 is N, S or O; provided that X 1 and X 2 are different;R 1 is hydrogen; n is 1 or 2; A 1 is methylene or ethane-1,2-diyl; A 2 is methylene, ethane-1,2-diyl or propane-1,3-diyl; R 2 is hydrogen or methyl; or A 1 and R 2 form, together with the nitrogen atom to which they are attached, an unsubstituted four-membered ring; R 3represents one or two optional substituents, which are independently -F and Cl, -Cyano, -trifluoromethyl, -methoxy, and -Carboxyl group may be selected from the group consisting of: R 4 teeth, -hydrogen, -Cl, -methyl, and -trifluoromethyl is selected from the group consisting of:
[0147] Optionally, the salt is selected from salts of the compound of formula (I) with an acid selected from the group consisting of benzoic acid, citric acid, fumaric acid, hydrochloric acid, lactic acid, malic acid, maleic acid, methanesulfonic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid and toluenesulfonic acid, characterized in that the ratio of compound (I):acid is 1-2:1-3.
[0148] In some embodiments of the compounds of Formula (I), X 1 is N or O; X 2 is N, S or O; provided that X 1 and X 2 are different;R 1 is hydrogen; n is 1; A 1 is methylene or ethane-1,2-diyl; A 2 is methylene, ethane-1,2-diyl or propane-1,3-diyl; R 2 is hydrogen; or A 1 and R 2 form an unsubstituted four-membered ring together with the nitrogen atom to which they are attached; R 3 represents a hydrogen atom, forming an unsubstituted terminal benzimidazolyl ring; R 4 teeth, -hydrogen, -Cl, and -methyl or its salts selected from the group consisting of: The salt is selected from salts of the compound of formula (I) with an acid selected from the group consisting of benzoic acid, citric acid, fumaric acid, hydrochloric acid, lactic acid, malic acid, maleic acid, methanesulfonic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid and toluenesulfonic acid, and is characterized in that the ratio of compound (I):acid is 1-2:1-3.
[0149] In some embodiments of the compounds of Formula (I), X 1 is N or O; X 2 is N, S or O; provided that X 1 and X 2 are different;R 1 is hydrogen; n is 1; A 1 is methylene or ethane-1,2-diyl; A 2 is methylene, ethane-1,2-diyl or propane-1,3-diyl; R 2 is hydrogen; or A 1 and R 2 form an unsubstituted four-membered ring together with the nitrogen atom to which they are attached; R 3 represents a hydrogen atom, forming an unsubstituted terminal benzimidazolyl ring; R 4 is hydrogen; or a salt thereof.
[0150] In some embodiments, the salt is selected from salts of a compound of Formula (I), (II), (III) or a compound according to WO2020 / 123850A1 as defined below with an acid selected from the group consisting of benzoic acid, citric acid, fumaric acid, hydrochloric acid, lactic acid, malic acid, maleic acid, methanesulfonic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, and toluenesulfonic acid, wherein the ratio of compound (I):acid is 1-2:1-3; and In some embodiments of the compounds of Formula (I), n=1; R 3 = hydrogen; R 4 = hydrogen; A 1 = ethane-1,2-diyl; A 2 = methylene, ethane-1,2-diyl or propane-1,3-diyl; R 2= hydrogen; or A 1 and R 2 together with the nitrogen atom to which they are attached to form an optionally substituted four-membered ring, thereby forming a compound according to formula (II) or (III): [ka] Forming Here, in formulas (II) and (III), m is an integer of 1, 2, or 3, and X 1 , X 2 , and R 1 has the meaning defined above in any embodiment involving compounds of formula (I).
[0151] In particular, in formulas (II) and (III), X 1 and X 2 has the meaning defined above in A).
[0152] In formula (II), R 1 and R 2 is preferably hydrogen.
[0153] In formula (III), R 1 is preferably hydrogen and m is preferably 2.
[0154] In a further preferred embodiment of the compounds of general formula (II), X 1 and X 2 are selected from N and O and are different; R 1 = hydrogen; R 2 = hydrogen; and m=2.
[0155] The salt-forming compounds of formula (I), (II), or (III), or compounds according to WO 2020 / 123850 A1 as defined below, are also referred to as "bases" or "free bases." In the form of a free base, a compound according to formula (I), (II), or (III), or compounds according to WO 2020 / 123850 A1 as defined below, has at least one basic group, such as an amino group, to which an acidic group can be attached.
[0156] The salts of the compounds of formula (I), (II) or (III) or of the compounds according to WO 2020 / 123850 A1 as defined below can be selected from salts having a ratio of base (compound (I), (II) or (III)):acid of 1-2:1-3, where for the salt-forming acid reference is made to the above-defined selection.
[0157] The compounds may be mixed salts of compounds (I), (II), or (III) with one or more of the acids set forth above, which may have the same or different base:acid ratios, and which provide counter anions for the cationic forms of compounds (I), (II), or (III).
[0158] Particularly preferred are the 3HCl salts of the compounds described above.
[0159] In a particularly preferred embodiment, the method comprises administering the 3HCl salt of Compound 127. [ka]
[0160] In a further embodiment of the invention, compound 127 may be administered in the form of one of the salts below.
[0161] A 1:1 sulfate having the formula: [ka] A 1:1 phosphate salt having the formula: [ka] 2:1 phosphate (hemiphosphate). [ka]
[0162] Further compounds that act as ferroportin inhibitors and are suitable for the treatment of SCD as defined herein are those described in WO2020 / 123850A1, which is incorporated herein by reference in its entirety. Particular compounds among those described in WO2020 / 123850A1 that are suitable for the treatment of SCD as defined herein can be selected from the group consisting of:
[0163] [Table 4]
[0164] The compound described in WO2020 / 123850A1 and selected from the above group can be provided as a new combination therapy for treating SCD by administering the compound in a new combination therapy with a fetal hemoglobin (HbF) inducer. In a preferred embodiment, the compound 2-(2-{[2-(1H-1,3-benzodiazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-[1,3]oxazolo[4,5-c]pyridin-4-amine is provided in combination therapy with a fetal hemoglobin (HbF) inducer for treating SCD. [Brief explanation of the drawings]
[0165] [Figure 1]Effect of Compound 127 on hemolysis of RBCs from Townes mice. Plasma levels of cell-free Hb, heme, and lactate dehydrogenase (LDH) are shown. Hemolysis markers were measured using commercially available kits (cell-free Hb kit #CSB E09632h, Cusabio; heme assay kit #MAK316, Sigma-Aldrich) according to the manufacturer's instructions. LDH was measured in plasma using a Hitachi clinical chemistry automated analyzer. Individual values and mean ± SD are shown. Statistical analysis was performed by comparing all treatment groups with the HbSS vehicle group using one-way ANOVA with Dunnett's multiple comparison test; *p<0.05, **p<0.01, ***p<0.001, n=9-10 mice / group). [Figure 2] RBC index in Townes mice treated with Compound 127 or vehicle for 6 weeks. Individual values and mean ± SD are shown, and statistical analysis was performed by comparing all treatment groups with the HbSS vehicle group using one-way ANOVA with Dunnett's multiple comparison test, *p<0.05, **p<0.01, ***p<0.001, n=9-10 mice / group. [Figure 3] Compound 127 corrected high WBC counts in Townes mice. Individual values and mean ± SD are shown, and statistical analysis was performed by comparing all treatment groups with the HbSS vehicle group using one-way ANOVA with Dunnett's multiple comparison test, *p<0.05, **p<0.01, ***p<0.001, n=5-10 mice / group. [Figure 4] Compound 127 reduced spleen and liver size in Townes mice. Individual values and mean ± SD are shown, and statistical analysis was performed by comparing all treatment groups with the HbSS vehicle group using one-way ANOVA with Dunnett's multiple comparison test, *p<0.05, **p<0.01, ***p<0.001, n=9-10 mice / group. [Figure 5]Total and 58Fe organ iron levels in Townes mice treated with Compound 127 or vehicle for 6 weeks. Individual values and mean ± SD are shown, and statistical analysis was performed by comparing all treatment groups with the HbSS vehicle group using one-way ANOVA with Dunnett's multiple comparison test, *p<0.05, **p<0.01, ***p<0.001, n=8-10 mice / group. [Figure 6] Compound 127 reduced the percentage of mature RBCs containing mitochondria in sickle cell mice treated with Compound 127 for 6 weeks. [Figure 7] Compound 127 reduced plasma levels of sVCAM-1 in Townes mice. sVCAM-1 was measured by ELISA. Individual values and mean ± SD are shown. Statistical analysis was performed by comparing all treatment groups with the HbSS vehicle group using one-way ANOVA with Dunnett's multiple comparison test; *p<0.05, **p<0.01, ***p<0.001, n=6-9 mice / group). [Figure 8] Plasma iron was measured 3 hours after the final dose of Compound 127 on Days 43 / 44. Individual values and mean ± SD are shown. Significant differences compared to the HbSS vehicle group are indicated: *p<0.05, **p<0.01, ***p<0.001 (one-way ANOVA with Dunnett's multiple comparison test). [Figure 9] MCHC (left) and CHCM (right) in HbSS and HbAA mice on day 43 / 44 measured using a Siemens Advia 120 automated hematology analyzer. Individual values and mean ± SD are shown. Significant differences compared to the HbSS vehicle group are indicated: *p<0.05, **p<0.01, ***p<0.001 (one-way ANOVA with Dunnett's multiple comparison test). [Figure 10]Percentage of hypochromic (top left), microcytic (top right), hyperchromic (bottom left), and macrocytic (bottom right) RBCs in male and female HbSS and HbAA on day 43 / 44 measured using a Siemens Advia 120 automated hematology analyzer. Individual values and mean ± SD are shown. Significant differences versus the HbSS vehicle group are indicated: *p<0.05, **p<0.01, ***p<0.001 (one-way ANOVA with Dunnett's multiple comparison test). [Figure 11] Total and indirect bilirubin in plasma of HbSS and HbAA mice on study day 43 / 44. Individual values and mean ± SD are shown. Significant differences compared to the HbSS vehicle group are indicated: *p<0.05, **p<0.01, ***p<0.001 (one-way ANOVA with Dunnett's multiple comparison test). [Figure 12] Plasma levels of sP-selectin (left) and RANTES (right) in plasma of HbSS and HbAA mice at the end of the study. Significant differences compared to the HbSS vehicle group are indicated: *p<0.05, **p<0.01, ***p<0.001 (one-way ANOVA with Dunnett's multiple comparison test). [Figure 13] Plasma xanthine oxidase (XO) activity and intracellular ROS in whole blood from HbSS and HbAA mice. Plasma XO activity and the percentage of ROS-positive mature RBCs are shown as individual values and mean ± SD. Significant differences compared to the HbSS vehicle group are indicated: *p<0.05, **p<0.01, ***p<0.001 (one-way ANOVA with Dunnett's multiple comparison test). [Figure 14] Compound 127 reduced intracellular iron (56Fe and 58Fe) in RBCs of Townes mice. The intracellular content of 56Fe and 58Fe was measured in washed RBCs from Townes mice by ICP-MS and normalized to RBC count. Individual values and mean ± SD are shown. Statistical analysis was performed by comparing all treatment groups with the HbSS vehicle group using one-way ANOVA with Dunnett's multiple comparison test, *p<0.05, n=6-9 mice / group. [Figure 15]Compound 127 reduced periportal inflammation and chemokine CXCL1 mRNA expression in the livers of Townes mice. The development of periportal inflammation was assessed using H&E-stained paraffin sections. CXCL1 mRNA expression from total liver RNA was assessed by RT-qPCR. Individual scores or individual ΔCt and mean ± SD are shown. Statistical analysis was performed by comparing all treatment groups with the HbSS vehicle group using one-way ANOVA with Dunnett's multiple comparison test; *p<0.05, **p<0.01, ***p<0.001, n=7-11 mice / group). [Figure 16] Compound 127 reduced biomarkers of liver injury. Plasma alanine transaminase (ALT) activity was measured using a Hitachi automated clinical chemistry analyzer. Individual values and mean ± SD are shown. Statistical analysis was performed using an unpaired, two-tailed Student's t-test; *p<0.05, **p<0.01, ***p<0.001, n=9-10 mice / group). [Figure 17] Compound 127 reduced IL-1β mRNA expression in the lungs of Townes mice. IL-1β mRNA expression from total lung RNA was assessed by RT-qPCR. Individual ΔCt and mean ± SD are shown. Statistical analysis was performed by comparing all treatment groups with the HbSS vehicle group using one-way ANOVA with Dunnett's multiple comparison test, *p<0.05, n=8-12 mice / group.
[0166] In Figures 1-17, "VIT-2763" refers to compound 127 (in the form of its 3HCl salt). DETAILED DESCRIPTION OF THE INVENTION
[0167] Townes mice have been genetically engineered to express exclusively human sickle hemoglobin (Ryan et al. 1990 Science 247:566). Townes mice have anemia, elevated reticulocyte counts, enlarged spleens, and vascular inflammation, making them susceptible to VO in response to hypoxia, inflammation, and hemolysis.
[0168] In the studies described below, male and female mice homozygous for human HbS (HbSS) and control mice expressing wild-type (WT) human hemoglobin HbA (HbAA) were used.
[0169] First test (Figures 1-7): Mice were purchased from Jackson Laboratories at 10-12 weeks of age (B6; 129 Hbbtm2(HBG1,HBB*)Tow / Hbbtm3(HBG1,HBB)Tow Hbatm1(HBA)Tow / J, product no. 013071; "Townes mice") and fed a low-iron diet (10-13 ppm iron, Granovit) and orally administered (bid) 60 or 120 mg / kg of Compound 127 or vehicle (0.5% methylcellulose / water) twice daily, excluding weekends, for 6 weeks. Between compound doses, mice were fed a stable iron isotope (250 ppm iron) instead of the iron present in the standard rodent diet. 58 Fe(1 mM) supplemented with 10 mM ascorbic acid as a reducing agent 58 The mice were given drinking water containing Fe(II)SO4. 58 Fe allowed us to distinguish between iron absorbed during the test and iron absorbed before the test.
[0170] Second test (Figures 8-13): HbS (HbSS) homozygous Townes mice (6 weeks old, Jackson Laboratories, part number 013071) were fed a low-iron diet (LID, Granovit, catalog 2039, batch 0001906903, iron content 8.6 mg / kg) and orally administered Compound 127 at 60 mg / kg twice daily (bid) or 0.5% methylcellulose (MC) as vehicle. Mice were treated with 1 mM sulfuric acid for 6 hours after the initial dose. 58 They received drinking water (DW) supplemented with Fe(II) and 10 mM ascorbic acid. 58The Fe(II) concentration was adjusted to complement dietary iron supplementation to the level of a standard rodent chow containing 250 mg / kg iron. Iron- and ascorbic acid-free water was provided for the remaining 18 hours. Non-sickle Townes mice (HbAA) expressing normal human hemoglobin (wild-type, WT) were administered vehicle twice daily and served as controls. Compound 127 or vehicle administration followed by 24 h of serotonin production was observed. 58 Exposure to Fe-containing water was repeated for 44 days. Treatment was suspended on weekends (WE), and mice were given LID and 58 Fe-free mineral water was available ad libitum.
[0171] Plasma iron was measured using the MULTIGENT iron assay (Abbott Diagnostics).
[0172] Hematological parameters were measured on whole blood samples taken on the last day of the study (day 43 / 44) and measured using a Siemens Advia ADVIA 120 system.
[0173] ROC in RBCs was detected with the indicator chloromethyl-2′,7′-dichlorodifluorescein diacetate (CM-H2DCFDA, Invitrogen, catalog no. C6827) in mature RBCs labeled with APC-eFluor780-conjugated rat anti-mouse Ter119 antibody and PE-conjugated rat anti-mouse CD71 antibody (eBioscience, catalog nos. 47-5921-82 and 12-0711).
[0174] The activity of xanthine oxidase in plasma was measured using a xanthine oxidase activity assay kit (Sigma-Aldrich catalogue number MAK078).
[0175] Plasma bilirubin was measured using an assay kit (Sigma-Aldrich catalogue number MAK126) according to the manufacturer's instructions.
[0176] Plasma sP-selectin and RANTES were measured using ELISA kits (R&D Systems, catalog numbers MVC00 and DY478-05, respectively) according to the manufacturer's instructions.
[0177] The activity of compound 127 in preventing VO for the treatment of sickle cell anemia (sickle cell disease) can be measured using mouse models described in WO2018 / 192973, such as those described in Yulin Zhao et al., "MEK1 / 2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease"; The FASEB Journal Vol. 30, No. 3, pp. 1171-1186, 2016. Such mouse models can be suitably adapted to measure the activity of compound 127 or compounds of further embodiments of the present invention in treating VO in sickle cell anemia. Suitable adaptations to optimized test conditions can be performed, which are within the routine of a person skilled in the art.
[0178] The two studies described in Examples 1-17 use the 3HCl salt of compound 127.
[0179] Example 1: Compound 127 reduced hemolysis in Townes mice.
[0180] Red blood cells from Townes mice are prone to hemolysis, as indicated by elevated levels of cell-free Hb, heme, and LDH in the vehicle-treated control HbSS group (Figure 1). Notably, compound 127 significantly reduced the levels of cell-free Hb, heme, and LDH, suggesting that ferroportin inhibition by compound 127 reduced hemolysis in Townes mice (Figure 1).
[0181] Example 2: Effect of Compound 127 on RBC Indices First test (Figures 1-7): HbSS mice are anemic, exhibiting pathological changes in blood parameters indicative of hemolytic anemia, such as decreased RBC count, Hb, and compensated reticulocytosis and elevated white blood cell count, compared with HbAA mice. Blood parameters were measured on fresh EDTA-blood using an automated hematology analyzer after 6 weeks of treatment with compound 127. Oral administration of compound 127 to HbSS mice for 6 weeks reduced total Hb, RBC count, hematocrit, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH). Reduction of HbS in RBCs in SCD patients has been associated with reduced HbS aggregation and clinical benefits (Castro O. Am. J. Hematol., 1994).
[0182] Second test (Figures 8-13): Townes HbSS mice have plasma iron levels similar to HbAA controls. In a second study, compound 127 was administered to HbSS mice at 60 mg / kg twice daily for 44 days, and plasma iron was measured 3 hours after the final dose of compound as a marker of acute efficacy. Plasma iron concentrations in HbSS mice treated with compound 127 were significantly reduced, indicating that compound 127 has the effect of inhibiting iron transport into the blood circulation (Figure 8).
[0183] Additionally, mean corpuscular hemoglobin concentration (MCHC) was significantly reduced in Townes mice treated with compound 127 (Figure 9, left). MCHC is calculated by dividing the mean Hb concentration in lysed blood by the hematocrit. In hemolytic diseases such as SCD, the presence of free Hb in hemolyzed blood samples can lead to erroneous overestimation of MCHC values. Therefore, to avoid potential artifacts due to excessive hemolysis in Townes mice, the HbS concentration in RBCs was assessed based on the corpuscular Hb concentration mean (CHCM) parameter. CHCM is measured from laser light scattering and is used to back-calculate cellular Hb, which reflects the hemoglobin content in intact RBCs. CHCM was not affected by hemolysis and was significantly lower in HbSS mice treated with compound 127, further demonstrating that iron restriction with compound 127 reduces HbS concentrations in the SCD model (Figure 9, right). Furthermore, scatterplot analysis of RBC distribution based on RBC volume and Hb concentration revealed a significant increase in the percentage of hypocytic and microcytic RBCs, accompanied by a decrease in macrocytic RBCs, in HbSS mice treated with compound 127 (Figure 10). Hematological analysis of blood samples from Townes mice indicates that compound 127 induces iron-limited erythropoiesis by blocking ferroportin, resulting in reduced HbS concentrations in RBCs. Reduction of HbS in RBCs of SCD patients has been associated with reduced HbS aggregation and clinical benefit (Castro O. Am. J. Hematol., 1994). Therefore, HbS reduction by compound 127 may represent a novel therapeutic approach in SCD.
[0184] As shown in the first study, compound 127 attenuated hemolysis in Townes mice, as indicated by a decrease in cell-free Hb, heme, and LDH (Figure 1). Furthermore, as shown in the second study, compound 127 reduced clinically relevant hemolysis markers, total and indirect bilirubin, further supporting the compound's efficacy in reducing hemolysis (Figure 11).
[0185] Interaction of sRBCs, activated leukocytes, and free heme with the endothelium leads to vascular inflammation, promoting vascular occlusion and organ damage. Endothelial dysfunction in SCD is associated with elevated levels of soluble adhesion molecules such as sVCAM-1 and sP-selectin.
[0186] Two independent studies showed that compound 127 significantly reduced sVCAM-1 (Figure 7, first study) and sP-selectin (Figure 12, left, second independent study), suggesting that compound 127 may reduce vascular inflammation and thereby prevent vascular occlusion in the Townes model of SCD.
[0187] RBC-derived heme acts as a damage-associated molecular pattern (DAPM) that activates the innate immune system, resulting in oxidant production, inflammation, vascular occlusion, ischemia, and tissue damage (Belcher JD et al. J. Clin. Invest, 2006). Townes mice and SCD patients have elevated circulating leukocytes, which produce proinflammatory cytokines and chemokines, attracting additional inflammatory cells and activating the endothelium. For example, HbSS mice exhibit elevated plasma levels of the chemokine RANTES (CCL5), which is involved in leukocyte recruitment to inflammatory sites. Treatment with compound 127 significantly reduced RANTES levels in HbSS mice (Figure 12, right), suggesting that compound 127 not only reduces circulating leukocyte numbers (Figure 3) but also suppresses their pro-inflammatory activity.
[0188] Plasma xanthine oxidase (XO) activity is elevated in SCD patients and has been defined as a cause of intravascular superoxide and hydrogen peroxide production. Elevated XO activity has also been reported in the plasma of Townes mice (Osarogiagbon UR et al., Blood, 2000; Aslan M et al., PNAS, 2001) and is thought to be an important contributor to ROS production and oxidative tissue damage. Indeed, XO activity was significantly higher in HbSS mice than in HbAA mice. Compound 127 reduced XO activity in the plasma of HbSS mice, suggesting reduced vascular oxidative damage (Figure 13, left). Furthermore, flow cytometry analysis of intracellular ROS in blood cells using the fluorescent indicator CM-H2DCFDA revealed that the majority of RBCs from HbSS mice had elevated ROC levels, and treatment with 60 mg / kg bid compound 127 significantly reduced ROC levels (Figure 13, right).
[0189] The reduction in HbS by compound 127 may have a beneficial effect on sRBCs. Importantly, compound 127 significantly reduced the number of reticulocytes, which are highly expanded in SCD due to a compensatory response to hemolysis (Figure 2).
[0190] Together, these data clearly demonstrate the potential of compound 127 to reduce oxidative stress and vascular inflammation, which may result in decreased adhesion of blood cells to the vascular endothelium and ultimately prevent VO events in the Townes model of SCD.
[0191] Example 3: Effect of Compound 127 on WBC Index Leukocytosis in SCD is associated with increased incidence of pain crises, acute chest syndrome, stroke, and death (Platt, NEJM, 1991). Unexpectedly, treatment of Townes mice with compound 127 significantly reduced blood white blood cell counts, particularly neutrophils and lymphocytes (Figure 3). This data suggests that compound 127 may have beneficial effects on inflammation in SCD.
[0192] Example 4: Compound 127 reduced spleen and liver size in Townes mice.
[0193] The spleens of Townes mice are significantly enlarged (up to 7-fold larger than those of WT mice) due to stress-induced erythropoiesis. Notably, compound 127 reduced spleen size in Townes mice, demonstrating that compound 127 improves extramedullary erythropoiesis (Figure 4, left). Furthermore, compound 127 corrected the increased liver weight of Townes mice to a level close to that of WT mice (Figure 4, center). Kidney weights in Townes mice were within the range of those of WT littermates and were not altered by compound 127 treatment (Figure 4, right).
[0194] Example 5: Compound 127 prevented organ iron loading and reduced total kidney iron in Townes mice.
[0195] Townes mice accumulate excess iron in organs such as the liver, kidneys, and spleen as a result of intravascular and extravascular hemolysis of defective RBCs. Approximately one-third of hemolysis in SCD is intravascular due to mechanical disruption of deformed, inelastic sRBCs, while two-thirds is extravascular due to removal of abnormal sRBCs by macrophages (Hebbel RP, Am. J. Hematol., 2011). Furthermore, anemia increases the expression of hypoxia-inducible factor (HIF)-2α in the intestine, which leads to excessive iron absorption (Das N. et al., J. Biol. Chem., 2015).
[0196] Oral administration in rodent PK studies demonstrated that compound 127 is systemically available, suggesting that it can block iron excretion in all ferroportin-expressing tissues, including the duodenum (dietary iron absorption), liver (iron stores in hepatocytes and macrophages), and spleen (iron in macrophages forming senescent erythrocytes). To distinguish between the effects of compound 127 on iron already present in the organs and newly absorbed iron, mice were administered stable iron isotopes (SrI) during the study. 58Drinking water containing Fe was available. Total iron and thrombus iron in the organs of HbSS mice treated with vehicle or Compound 127 were measured. 58 Fe content was analyzed by inductively coupled plasma optical emission spectroscopy (ICP-OES) and inductively coupled plasma mass spectrometry (ICP-MS), respectively. Compound 127 did not alter total liver or spleen iron concentrations in Townes mice, consistent with ferroportin-mediated iron excretion from these tissues (Figure 5, upper left and center panels). Surprisingly, compound 127 significantly reduced total iron concentrations in the kidneys of Townes mice (Figure 5, upper right panel). Abnormalities in renal iron metabolism and cortical iron deposition are characteristic of SCD and are involved in renal complications (Vazquez-Meves G et al., Blood, 2016). Therefore, reducing renal iron by compound 127 may have beneficial effects on renal function in SCD.
[0197] Importantly, in the liver, kidney, and spleen of Townes mice treated with Compound 127, 58 Fe concentrations were significantly lower compared to those in vehicle-treated mice, indicating that compound 127 prevented further organ iron accumulation (FIG. 5, lower panel).
[0198] Example 6: Compound 127 reduced apoptotic markers and improved mitochondrial clearance in mature sRBCs from Townes mice.
[0199] Polymerization of HbS induces free radical formation, dehydration, and membrane damage in sRBCs, which may lead to cell apoptosis. Apoptotic red blood cells expose phosphatidylserine (PS) to the extracellular space, which signals red blood cells to be targeted for phagocytosis. PS exposure on RBCs was measured by Annexin V staining of RBCs and flow cytometry. Compound 127 dose-dependently reduced PS exposure on sRBCs, indicating that iron restriction improves membrane organization and potentially RBC survival (Figure 6, left).
[0200] Healthy RBC precursors remove mitochondria during terminal differentiation by mitophagy. Abnormal mitochondrial retention in mature RBCs has been reported in patients and mice with SCD (Jagadeeswaran et al., 2017). Mitochondrial retention in RBCs was examined by flow cytometry using Ter119 and CD71 antibodies to distinguish RBC maturation states, and mitochondria were detected by MitoTracker. Notably, red blood cells from Townes mice treated with compound 127 at both doses had a lower percentage of mature RBCs containing mitochondria (Figure 6, right). Mouse models with specific deletions in mitophagy genes showed reduced RBC survival due to mitochondrial retention (Sandoval et al., 2008; Mortensen et al., 2010). This strongly suggests that compound 127's reduction in the percentage of mitochondria-retaining RBCs in SCD may have a beneficial effect on RBC lifespan.
[0201] Example 7: Compound 127 reduced vascular inflammatory markers in the Townes model of SCD.
[0202] The interaction of sRBCs, activated leukocytes, and free heme with the endothelium leads to vascular inflammation and promotes VO and organ injury. Endothelial dysfunction in SCD is associated with elevated levels of soluble adhesion molecules, such as vascular adhesion molecule 1 (sVCAM-1). Consistent with the reduction in hemolysis (Figure 1) and leukocyte counts (Figure 3), treatment with compound 127 significantly reduced sVCAM-1 levels in Townes mice (Figure 7). This data indicates that compound 127 reduces vascular inflammation in the Townes model of SCD, which may prevent VO events.
[0203] Example 8: Determining the activity of Compound 127 in treating VO in sickle cell disease in a mouse model The methods described in WO 2018 / 192973 can be used to determine the activity of the ferroportin inhibitor compounds of the invention.
[0204] Using the mouse model described by Yulin Zhao et al. in "MEK1 / 2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease"; The FASEB Journal Vol. 30, No. 3, pp 1171-1186, 2016, the activity of compound 127 in treating sickle cell disease can be determined as follows.
[0205] Vaso-occlusive (VO) stroke is a major cause of morbidity and mortality in patients with SCD. Hypoxia, dehydration, inflammation, or hemolysis all contribute to increased adhesion of sickled RBCs, neutrophils, and platelets to activated endothelium in small blood vessels, promoting coagulation, vaso-occlusion, painful stroke, and irreversible multi-organ damage. High white blood cell counts, particularly activated neutrophils, have been correlated with early death, silent cerebral infarction, hemorrhagic stroke, and acute chest syndrome in patients with SCD (Platt OS, NEJM, 1994). Hemolysis in SCD results from damage to the sickled RBC membrane, causing chronic anemia and release of Hb into the circulation, which promotes inflammation by depleting NO, generating oxidative stress, and releasing heme. Sickle RBCs release microvesicles that induce reactive oxygen species (ROS) production by endothelial cells, promote leukocyte adhesion, and induce endothelial apoptosis in a phosphatidylserine-dependent manner, which contributes to acute VO in SCD (Camus M, Blood, 2012).
[0206] Based on this data, it can be hypothesized that compounds of the present invention may alleviate VO in SCD by reducing hemolysis in sickle RBCs and subsequently preventing leukocyte adhesion to the endothelium.
[0207] To test this hypothesis, vehicle or a compound of the present invention was orally administered at 30 or 100 mg / kg twice daily (BID) for 4 weeks in the Townes mouse model of SCD (Ryan T, Science, 1990). These mice were genetically engineered to express exclusively human hemoglobin (hα / hα:βS / βS, The Jackson Laboratories). Townes mice have anemia, elevated reticulocyte counts, an enlarged spleen, and vascular inflammation, making them susceptible to VO2 in response to hypoxia, inflammation, and hemolysis. To examine the effects of ferroportin inhibitors on leukocyte and sickle cell adhesion to inflamed endothelium, Townes mice treated with vehicle or ferroportin inhibitors for 25 days were anesthetized and surgically implanted with a fenestrated chamber into the dorsal skin fold under sterile conditions, according to previously published methods (Kalambur VS et al., Am J Hematol, 2004; Zennadi, R et al., Blood, 2007). Three days after surgery, mice were injected with 0.5 μg of TNFα (R&D Systems) to induce inflammation, resulting in VO. Ninety minutes after TNFα administration, leukocytes and RBCs were labeled in vivo by intravenous injection of rhodamine-conjugated Ly6G (Sigma) and phycoerythrin-conjugated anti-TER119 mAb (BioLegend), respectively. Adhesion of leukocytes and RBS to the microvascular endothelium was monitored for the following 90 min by fluorescence intravital microscopy according to previously published methods (Zhao et al., FASEB J, 2016). Anesthetized animals equipped with a windowed chamber were maintained at 37 °C, and blood flow and cell adhesion events were recorded using a digital video camera C2400 (Hamamatsu Photonics Co., Ltd., Hamamatsu, Japan) connected to a fluorescence microscope (Axoplan microscope, Carl Zeiss). Twenty to thirty microcapillary segments per mouse were examined, and cell adhesion was quantified on still images by measuring the fluorescence intensity of attached fluorescently labeled cells using ImageJ software. Results were expressed as fluorescence units per million cells.
[0208] Conclusion: In summary, iron restriction with the oral ferroportin inhibitor compound 127 significantly reduced hemolysis, oxidative stress, vascular and systemic inflammation, and improved RBC morphology, thereby attenuating vaso-occlusive events and improving hemodynamics in the Townes model of SCD.
[0209] Ferroportin inhibitors prevent acute vascular obstruction and organ damage in a mouse model of sickle cell disease.
[0216] Other embodiments It should be understood that while the invention has been described above in conjunction with a detailed description thereof, the foregoing description is intended to be illustrative, but not limiting, of the scope of the invention, which is defined by the appended claims. Other aspects, advantages, and modifications are intended to be encompassed within the following claims.
Claims
1. A pharmaceutical composition comprising the 3HCl salt of a compound according to the formula: 【Chemistry 3】
2. 2. The pharmaceutical composition for use according to claim 1, wherein the sickle cell disease is selected from HbSS; HbSC; HbSβ0 thalassemia; HbSβ+ thalassemia, HbSD, HbSE and HbSO.
3. 3. A pharmaceutical composition for use according to claim 1 or 2, in a form for oral administration.
4. A pharmaceutical composition for use according to any one of claims 1 to 3, in the form of a filled capsule for oral administration.
5. 5. A pharmaceutical composition for use according to any one of claims 1 to 4, wherein said treatment comprises administering to a patient in need thereof a daily dose of 5 mg, 15 mg, 30 mg, 60 mg, 120 mg or 240 mg of said salt.
6. 6. The pharmaceutical composition for use according to any one of claims 1 to 5, wherein said treatment comprises administering to a patient in need thereof a daily dose of 30 mg or 60 mg of said salt for patients weighing 50 kg or more and 100 kg or less.
7. 7. A pharmaceutical composition for use according to claim 5 or 6, wherein said treatment comprises administering to a patient in need of treatment a selected daily dose of said salt once or twice daily.
8. A combination therapy composition, wherein the pharmaceutical composition for use according to any one of claims 1 to 7 is present in a fixed dose or free dose combination with at least one additional pharma- ceutical active compound for sequential use for co-administration of said compound.
9. The combination therapy composition for use according to claim 8, wherein the at least one additional pharma- ceutical active compound is selected from the group of SCD drugs.
10. A combination therapy composition for use according to claim 8 or 9, wherein at least one additional pharma- ceutical active compound is selected from the group of hydroxyureas and / or pain relieving drugs.
Citation Information
Patent Citations
Novel ferroportin inhibitors
WO2017068089A2
Novel ferroportin inhibitors
WO2017068090A1
Ferroportin-inhibitor salts
WO2018192973A1
